Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
polyethylene glycol 400
- Development stage
- Phase 4
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Oral, Topical, Ophthalmic, Rectal
01
Overview
Polyethylene glycol 400 (PEG 400) is a low-molecular-weight grade of polyethylene glycol, characterized by an average molecular weight of approximately 400. It is a clear, colorless, viscous liquid with strong hydrophilic properties and very low toxicity. PEG 400 is widely used in pharmaceutical formulations as an excipient to enhance the solubility and bioavailability of poorly water-soluble drugs. In addition to its role as a solvent, plasticizer, surfactant, ointment base, suppository base, and tablet/capsule lubricant in drug manufacturing, it serves as an active ingredient in ophthalmic solutions for the relief of dry eye symptoms by acting as a synthetic ocular lubricant (lacrimomimetic). Polyethylene glycols are also used for PEGylation—attaching them to protein medications to improve their solubility and pharmacokinetics[1][2][3][4][5].
- Brand names
- Super Refined PEG 400Carbowax Polyethylene Glycol 400
- Other names
- polyethylene glycol 400PEG 400PEG400PEG-400
02
Targets
SULT1A1 (Sulfotransferase 1A1)CYP4A11 (Cytochrome P450 family 4 subfamily A member 11)GSNOR (S-nitrosoglutathione reductase)
Beyond the preview
Go deeper on polyethylene glycol 400.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on polyethylene glycol 400.